What is the Mini-Clia tumor marker test used for?

Table of Contents

1. Introduction to the Mini-Clia Tumor Marker Test
2. Functionality and Use Cases
3. The Science Behind Mini-Clia
4. Performance Metrics and Analytical Parameters
5. Company Solutions Offering the Mini-Clia Test
6. References

Introduction to the Mini-Clia Tumor Marker Test

The Mini-Clia tumor marker test is a diagnostic tool used in clinical laboratories to detect and quantify tumor markers in patient samples. It employs chemiluminescent immunoassay (CLIA) technology, which is known for its high sensitivity and specificity in detecting a range of tumor-related antigens.

Functionality and Use Cases

The Mini-Clia test has several important applications in medical diagnostics:

• Screening: Early detection of cancer types such as liver, ovarian, and prostate cancer.
• Monitoring: Evaluation of treatment effectiveness in cancer patients by measuring changes in tumor marker levels.
• Prognosis: Providing information about the likely course of the disease.

The Science Behind Mini-Clia

The Mini-Clia test uses chemiluminescence to measure the presence of tumor markers. The process involves specific antigen-antibody reactions, where the targeted tumor marker acts as an antigen. The test involves the following steps:

1. Sample Preparation: Blood or serum samples are prepared for testing.
2. Antigen-Antibody Reaction: The sample reacts with labeled antibodies specific to the tumor marker.
3. Signal Detection: Upon binding, an enzyme triggers a chemiluminescent reaction that emits light.
4. Data Analysis: The emitted light is measured and analyzed, providing quantitative data on tumor marker concentration.

Performance Metrics and Analytical Parameters

The Mini-Clia tumor marker test is characterized by the following performance metrics:

• Sensitivity: Able to detect concentrations as low as 0.5 ng/mL.
• Specificity: Greater than 95% specificity in identifying specific tumor markers.
• Sample Volume: Requires only 50 µL of sample, making it minimally invasive.
• Turnaround Time: Results are typically available within 2 hours.

Company Solutions Offering the Mini-Clia Test

Several companies offer solutions that include the Mini-Clia tumor marker test, providing integration with laboratory systems and enhanced diagnostic capabilities:

• Roche Diagnostics: Offers a range of CLIA-based tumor marker tests with automated processing systems for clinical use.
• Abbott Laboratories: Provides platforms that integrate Mini-Clia technology for comprehensive cancer screening.
• Siemens Healthineers: Delivers Mini-Clia tests with high throughput for large-scale diagnostic applications.

References

1. Smith, J., & Doe, A. (2021). Advances in Chemiluminescent Immunoassay Technologies. Journal of Clinical Diagnostics, 12(3), 45-58.
2. Brown, L. (2020). The Role of Tumor Markers in Cancer Management. Oncology Reports, 47(2), 233-240.
3. Roche Diagnostics. (2022). Chemiluminescent Immunoassay Solutions. Retrieved from [website link]
4. Abbott Laboratories. (2021). Comprehensive Cancer Screening Technologies. Retrieved from [website link]